317 related articles for article (PubMed ID: 35111663)
1. The Application of CRISPR/Cas9 Technology for Cancer Immunotherapy: Current Status and Problems.
Wang L; Chen Y; Liu X; Li Z; Dai X
Front Oncol; 2021; 11():704999. PubMed ID: 35111663
[TBL] [Abstract][Full Text] [Related]
2. CRISPR/Cas9 and CAR-T cell, collaboration of two revolutionary technologies in cancer immunotherapy, an instruction for successful cancer treatment.
Mollanoori H; Shahraki H; Rahmati Y; Teimourian S
Hum Immunol; 2018 Dec; 79(12):876-882. PubMed ID: 30261221
[TBL] [Abstract][Full Text] [Related]
3. The application of CRISPR-Cas9 genome editing tool in cancer immunotherapy.
Wu HY; Cao CY
Brief Funct Genomics; 2019 Mar; 18(2):129-132. PubMed ID: 29579146
[TBL] [Abstract][Full Text] [Related]
4. Advancing chimeric antigen receptor T cell therapy with CRISPR/Cas9.
Ren J; Zhao Y
Protein Cell; 2017 Sep; 8(9):634-643. PubMed ID: 28434148
[TBL] [Abstract][Full Text] [Related]
5. Applications and advances of CRISPR-Cas9 in cancer immunotherapy.
Xia AL; He QF; Wang JC; Zhu J; Sha YQ; Sun B; Lu XJ
J Med Genet; 2019 Jan; 56(1):4-9. PubMed ID: 29970486
[TBL] [Abstract][Full Text] [Related]
6. Combination of CRISPR/Cas9 System and CAR-T Cell Therapy: A New Era for Refractory and Relapsed Hematological Malignancies.
Hu KJ; Yin ETS; Hu YX; Huang H
Curr Med Sci; 2021 Jun; 41(3):420-430. PubMed ID: 34218353
[TBL] [Abstract][Full Text] [Related]
7. CRISPR/Cas9 Gene-Editing in Cancer Immunotherapy: Promoting the Present Revolution in Cancer Therapy and Exploring More.
Ou X; Ma Q; Yin W; Ma X; He Z
Front Cell Dev Biol; 2021; 9():674467. PubMed ID: 34095145
[TBL] [Abstract][Full Text] [Related]
8. Exploiting the CRISPR-Cas9 gene-editing system for human cancers and immunotherapy.
Afolabi LO; Afolabi MO; Sani MM; Okunowo WO; Yan D; Chen L; Zhang Y; Wan X
Clin Transl Immunology; 2021; 10(6):e1286. PubMed ID: 34188916
[TBL] [Abstract][Full Text] [Related]
9. Strengthening the CAR-T cell therapeutic application using CRISPR/Cas9 technology.
Sadeqi Nezhad M; Yazdanifar M; Abdollahpour-Alitappeh M; Sattari A; Seifalian A; Bagheri N
Biotechnol Bioeng; 2021 Oct; 118(10):3691-3705. PubMed ID: 34241908
[TBL] [Abstract][Full Text] [Related]
10. A deep insight into CRISPR/Cas9 application in CAR-T cell-based tumor immunotherapies.
Razeghian E; Nasution MKM; Rahman HS; Gardanova ZR; Abdelbasset WK; Aravindhan S; Bokov DO; Suksatan W; Nakhaei P; Shariatzadeh S; Marofi F; Yazdanifar M; Shamlou S; Motavalli R; Khiavi FM
Stem Cell Res Ther; 2021 Jul; 12(1):428. PubMed ID: 34321099
[TBL] [Abstract][Full Text] [Related]
11. CRISPR/Cas: From Tumor Gene Editing to T Cell-Based Immunotherapy of Cancer.
Azangou-Khyavy M; Ghasemi M; Khanali J; Boroomand-Saboor M; Jamalkhah M; Soleimani M; Kiani J
Front Immunol; 2020; 11():2062. PubMed ID: 33117331
[TBL] [Abstract][Full Text] [Related]
12. CRISPR-Cas9, A Promising Therapeutic Tool for Cancer Therapy: A Review.
Akram F; Ikram Ul Haq ; Ahmed Z; Khan H; Ali MS
Protein Pept Lett; 2020; 27(10):931-944. PubMed ID: 32264803
[TBL] [Abstract][Full Text] [Related]
13. Chimeric antigen receptor T cell therapy and other therapeutics for malignancies: Combination and opportunity.
Wang L; Yao R; Zhang L; Fan C; Ma L; Liu J
Int Immunopharmacol; 2019 May; 70():498-503. PubMed ID: 30875561
[TBL] [Abstract][Full Text] [Related]
14. Advancements in CRISPR screens for the development of cancer immunotherapy strategies.
Li YR; Lyu Z; Tian Y; Fang Y; Zhu Y; Chen Y; Yang L
Mol Ther Oncolytics; 2023 Dec; 31():100733. PubMed ID: 37876793
[TBL] [Abstract][Full Text] [Related]
15. Novelty in improvement of CAR T cell-based immunotherapy with the aid of CRISPR system.
Hajifathali A; Lasemi MV; Mehravar M; Moshari MR; Alizadeh AM; Roshandel E
Hematol Transfus Cell Ther; 2024; 46(1):58-66. PubMed ID: 37451978
[TBL] [Abstract][Full Text] [Related]
16. CRISPR Gene Editing of Human Primary NK and T Cells for Cancer Immunotherapy.
Elmas E; Saljoughian N; de Souza Fernandes Pereira M; Tullius BP; Sorathia K; Nakkula RJ; Lee DA; Naeimi Kararoudi M
Front Oncol; 2022; 12():834002. PubMed ID: 35449580
[TBL] [Abstract][Full Text] [Related]
17. CRISPR, CAR-T, and NK: Current applications and future perspectives.
Khoshandam M; Soltaninejad H; Hamidieh AA; Hosseinkhani S
Genes Dis; 2024 Jul; 11(4):101121. PubMed ID: 38545126
[TBL] [Abstract][Full Text] [Related]
18. CRISPR/Cas9 system: recent applications in immuno-oncology and cancer immunotherapy.
Chen C; Wang Z; Qin Y
Exp Hematol Oncol; 2023 Nov; 12(1):95. PubMed ID: 37964355
[TBL] [Abstract][Full Text] [Related]
19. CRISPR-Cas9 for cancer therapy: Opportunities and challenges.
Chen M; Mao A; Xu M; Weng Q; Mao J; Ji J
Cancer Lett; 2019 Apr; 447():48-55. PubMed ID: 30684591
[TBL] [Abstract][Full Text] [Related]
20. Improving Cancer Immunotherapy with CRISPR-Based Technology.
Li Z; Fei T
Adv Biosyst; 2020 Nov; 4(11):e1900253. PubMed ID: 33245213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
